Erratum: Sustained release of transgenic human factor IX: Preparation, characterization, and in vivo efficacy (Molecular Pharmaceutics (2011) 8 (1767-1774) DOI:10.1021/mp200133s);Sustained release of transgenic human factor IX: Preparation, characterization, and in vivo efficacy

Molecular Pharmaceutics

Volumn 8, Issue 5, 2011, Pages 1767-1774

  Chang, Li Chien ^a   Yang, Chi Yu ^b   Chua, Anna Chian New ^a   Lin, Yi Juain ^b   Lai, Sun Mou ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b ANIMAL TECHNOLOGY INSTITUTE TAIWAN   (Taiwan)

^c NATIONAL ILAN UNIVERSITY   (Taiwan)

Author keywords

hemophilia B; long acting preparation; microsphere; prophylaxis; transgenic factor IX

Indexed keywords

BLOOD CLOTTING FACTOR 9; MICROSPHERE; POLYGLACTIN; RECOMBINANT HUMAN BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; DRUG SYNTHESIS; HEMOPHILIA B; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

EID: 80053545184     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200525q     Document Type: Erratum

References (26)

1. Peyvandi, F.; Jayandharan, G.; Chandy, M.; Srivastava, A.; Nakaya, S. M.; Johnson, M. J.; Thompson, A. R.; Goodeve, A.; Garagiola, I.; Lavoretano, S.; Menegatti, M.; Palla, R.; Spreafico, M.; Tagliabue, L.; Asselta, R.; Duga, S.; Mannucci, P. M. Genetic diagnosis of haemophilia and other inherited bleeding disorders Haemophilia 2006, 12 (Suppl. 3) 82-9
2. Key, N. S.; Negrier, C. Coagulation factor concentrates: past, present, and future Lancet 2007, 370, 439-48 (Pubitemid 47176658)
3. Matrai, J.; Chuah, M. K.; VandenDriessche, T. Preclinical and clinical progress in hemophilia gene therapy Curr. Opin. Hematol. 2010, 17, 387-92
4. Zhang, G.; Shi, Q.; Fahs, S. A.; Kuether, E. L.; Walsh, C. E.; Montgomery, R. R. Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice Blood 2010, 116, 1235-43
5. Peters, R. T.; Low, S. C.; Kamphaus, G. D.; Dumont, J. A.; Amari, J. V.; Lu, Q.; Zarbis-Papastoitsis, G.; Reidy, T. J.; Merricks, E. P.; Nichols, T. C.; Bitonti, A. J. Prolonged activity of factor IX as a monomeric Fc fusion protein Blood 2010, 115, 2057-64
6. Sheffield, W. P.; Mamdani, A.; Hortelano, G.; Gataiance, S.; Eltringham-Smith, L.; Begbie, M. E.; Leyva, R. A.; Liaw, P. S.; Ofosu, F. A. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits Br. J. Haematol. 2004, 126, 565-73 (Pubitemid 39093100)
7. Hartmann, R.; Dockal, M.; Kammlander, W.; Panholzer, E.; Nicolaes, G. A.; Fiedler, C.; Rosing, J.; Scheiflinger, F. Factor IX mutants with enhanced catalytic activity J. Thromb. Haemostasis 2009, 7, 1656-62
8. Mannucci, P. M. Back to the future: a recent history of haemophilia treatment Haemophilia 2008, 14 (Suppl. 3) 10-8 (Pubitemid 351722377)
9. Manco-Johnson, M. J.; Abshire, T. C.; Shapiro, A. D.; Riske, B.; Hacker, M. R.; Kilcoyne, R.; Ingram, J. D.; Manco-Johnson, M. L.; Funk, S.; Jacobson, L.; Valentino, L. A.; Hoots, W. K.; Buchanan, G. R.; DiMichele, D.; Recht, M.; Brown, D.; Leissinger, C.; Bleak, S.; Cohen, A.; Mathew, P.; Matsunaga, A.; Medeiros, D.; Nugent, D.; Thomas, G. A.; Thompson, A. A.; McRedmond, K.; Soucie, J. M.; Austin, H.; Evatt, B. L. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia N. Engl. J. Med. 2007, 357, 535-44 (Pubitemid 47236278)
10. Hansen, L.; Oestergaard, H.; Tranholm, M.; Agersoe, H. In The pharmacokinetics of a long-acting factor ix (40K PEG-RFIX) in minipigs suggests at least a once-weekly dosing regimen. J. Thromb. Haemostasis 2009, 7 (Suppl. 2), abstract #OC-MO-085.
11. Elm, T.; Oestergaard, H.; Tranholm, M. In Dose response and prolonged effect of 40K PEG-FIX on bleeding in hemophilia B mice. J. Thromb. Haemostasis 2009, 7 (Suppl. 2), abstract #OC-MO-084.
12. Bayer, R. J.; Ostergaard, H.; M.S., K.; Holm, P. K.; Kinealy, K.; Sarensen, B. B.; Bjarn, S. E.; Zopf, D.; Stennicke, H. R. In Development of long-acting FIIa derivatives by glycopegylation. J. Thromb. Haemostasis 2007, 5 (Suppl. 2), abstract #P-T-016.
13. Crotts, G.; Park, T. G. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues J. Microencapsulation 1998, 15, 699-713 (Pubitemid 28490941)
14. Cohen, S.; Yoshioka, T.; Lucarelli, M.; Hwang, L. H.; Langer, R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres Pharm. Res. 1991, 8, 713-20
15. Wu, S. C.; Cheng, T. K.; Chen, C. M.; Lin, S. P.; Yen, C. H.; Yang, P. C. Method for expressing multiple recombinant proteins in milk of transgenic non-human mammals. U.S. Patent 7,087,808, 2006.
16. Chang, C. H.; Chou, T. K.; Yang, C. Y.; Chang, T. J.; Wu, Y. H.; Lee, T. W. Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats In Vivo 2008, 22, 693-7
17. Lillicrap, D. Improvements in factor concentrates Curr. Opin. Hematol. 2010, 17, 393-7
18. Lin, H. F.; Maeda, N.; Smithies, O.; Straight, D. L.; Stafford, D. W. A coagulation factor IX-deficient mouse model for human hemophilia B Blood 1997, 90, 3962-6 (Pubitemid 27484049)
19. McCraw, A.; Hillarp, A.; Echenagucia, M. Considerations in the laboratory assessment of haemostasis Haemophilia 2010, 16 (Suppl. 5) 74-8
20. Chowdary, P.; Dasani, H.; Jones, J. A.; Loran, C. M.; Eldridge, A.; Hughes, S.; Collins, P. W. Recombinant factor IX (BeneFIX) by adjusted continuous infusion: a study of stability, sterility and clinical experience Haemophilia 2001, 7, 140-5 (Pubitemid 32243795)
21. National Hemophilia Foundation no. 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). November 2007. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx? menuid=57&contentid=1007. Accessed November 4, 2007.
22. Yeung, P. K. Transgenic antithrombin III (Genzyme) IDrugs 2000, 3, 669-73
23. Estey, T.; Kang, J.; Schwendeman, S. P.; Carpenter, J. F. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems J. Pharm. Sci. 2006, 95, 1626-39 (Pubitemid 44049129)
24. Ding, A. G.; Schwendeman, S. P. Acidic microclimate pH distribution in PLGA microspheres monitored by confocal laser scanning microscopy Pharm. Res. 2008, 25, 2041-52
25. Huang, M.; Furie, B. C.; Furie, B. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody J. Biol. Chem. 2004, 279, 14338-46 (Pubitemid 38468975)
26. Holm, P. K.; Petersen, L. C.; Bjelke, J. R.; Pedersen, A. A.; Hansen, L.; Hermit, M. B.; Petersen, J. M.; Krogh, T. N.; Andersen, M. D.; Tranholm, M.; Bjorn, S. E.; Ostergaard, H. In Prolonged In Vivo half-life and retained activity of factor IX glycopegylated in the activation peptide. J. Thromb. Haemostasis 2009, 7 (Suppl. 2), abstract #PP-MO-575.